Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18929510 | METHODS FOR THE TREATMENT OF THYROID EYE DISEASE | October 2024 | February 2025 | Allow | 4 | 1 | 0 | Yes | No |
| 18804738 | INTERLEUKIN 21 VARIANTS | August 2024 | January 2025 | Allow | 5 | 1 | 0 | No | No |
| 18790955 | ANTI-GPRC5D ANTIBODIES AND COMPOSITIONS | July 2024 | December 2024 | Allow | 4 | 0 | 1 | No | No |
| 18671801 | TREATMENT OF INFLAMMATORY CONDITIONS BY DELIVERY OF INTERLEUKIN-1 RECEPTOR ANTAGONIST FUSION PROTEIN | May 2024 | October 2024 | Allow | 5 | 1 | 0 | No | No |
| 18656092 | ANTI-SLC34A2 MONOCLONAL ANTIBODIES AND USES THEREOF | May 2024 | September 2024 | Allow | 5 | 0 | 1 | No | No |
| 18656236 | IL23R BINDING MOLECULES AND METHODS OF USE | May 2024 | March 2025 | Abandon | 10 | 0 | 1 | No | No |
| 18583481 | ERBB-2 AND ERBB-3 BINDING BISPECIFIC ANTIBODIES FOR USE IN THE TREATMENT OF CELLS THAT HAVE AN NRG1 FUSION GENE | February 2024 | November 2024 | Allow | 8 | 2 | 0 | No | No |
| 18431767 | METHODS OF USING IMMUNOTHERAPEUTICS THAT BIND FOLATE RECEPTOR ALPHA | February 2024 | February 2025 | Allow | 12 | 1 | 1 | No | No |
| 18426199 | HOMODIMERIC ANTIBODIES FOR USE IN TREATING CANCERS AND METHODS OF USE | January 2024 | January 2025 | Allow | 12 | 1 | 1 | No | No |
| 18402604 | COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | January 2024 | August 2024 | Allow | 7 | 2 | 0 | No | No |
| 18556606 | ANTI-CLDN4/ANTI-CD137 BISPECIFIC ANTIBODY | October 2023 | October 2024 | Allow | 12 | 1 | 1 | No | No |
| 18555338 | HYPERIMMUNIZED EGG PRODUCT FOR TREATING OR PREVENTING ALCOHOLIC LIVER DISEASE AND GRAFT-VERSUS-HOST DISEASE | October 2023 | May 2025 | Allow | 19 | 2 | 1 | No | No |
| 18331422 | PHARMACEUTICAL COMPOSITION COMPRISING ANTI-HUMAN TSLP RECEPTOR ANTIBODY | June 2023 | June 2025 | Allow | 25 | 1 | 0 | No | No |
| 18327091 | TRANSFERRIN BINDING ANTIBODIES AND USE THEREOF | June 2023 | July 2024 | Allow | 13 | 1 | 1 | Yes | No |
| 18193030 | Artificial Cell Death Polypeptide For Chimeric Antigen Receptor And Uses Thereof | March 2023 | August 2024 | Allow | 16 | 2 | 2 | No | No |
| 18189065 | ANTI-FLT-1 ANTIBODIES FOR TREATING DUCHENNE MUSCULAR DYSTROPHY | March 2023 | June 2025 | Allow | 26 | 1 | 1 | No | No |
| 18068237 | Anti-MARCO Antibodies and Uses Thereof | December 2022 | April 2025 | Allow | 27 | 1 | 0 | No | No |
| 18058239 | THERAPEUTIC ANTIBODIES AGAINST ROR-1 PROTEIN AND METHODS FOR USE OF SAME | November 2022 | September 2024 | Allow | 22 | 0 | 0 | No | No |
| 18047988 | CHIMERIC ANTIGEN RECEPTORS AGAINST MULTIPLE HLA-G ISOFORMS | October 2022 | January 2025 | Allow | 27 | 1 | 0 | No | No |
| 18046082 | COMPOSITIONS FOR INCREASING HALF-LIFE OF A THERAPEUTIC AGENT IN FELINES AND METHODS OF USE | October 2022 | February 2025 | Allow | 28 | 1 | 1 | No | No |
| 17933709 | TARGETING CELL TROPISM RECEPTORS TO INHIBIT CYTOMEGALOVIRUS INFECTION | September 2022 | December 2024 | Allow | 26 | 1 | 0 | No | No |
| 17942695 | TGF-BETA SUPERFAMILY TYPE I AND TYPE II RECEPTOR HETEROMULTIMERS AND USES THEREOF | September 2022 | May 2025 | Allow | 32 | 2 | 0 | No | No |
| 17929572 | TREATMENT OF INFLAMMATORY CONDITIONS BY DELIVERY OF INTERLEUKIN-1 RECEPTOR ANTAGONIST FUSION PROTEIN | September 2022 | March 2025 | Abandon | 30 | 1 | 0 | No | No |
| 17819161 | ANTI-IL-22R ANTIBODIES | August 2022 | March 2025 | Abandon | 31 | 1 | 0 | No | No |
| 17817295 | COMBINATION THERAPIES AND PATIENT STRATIFICATION WITH BISPECIFIC ANTI-EGFR/C-MET ANTIBODIES | August 2022 | September 2024 | Allow | 26 | 0 | 0 | No | No |
| 17814434 | COMPOSITIONS AND METHODS FOR TREATING CEACAM POSITIVE CANCERS | July 2022 | March 2025 | Allow | 32 | 1 | 1 | No | No |
| 17812256 | ANTI-GITR ANTIBODIES AND USES THEREOF | July 2022 | March 2025 | Abandon | 32 | 0 | 1 | No | No |
| 17847380 | TARGETED MODIFIED TNF FAMILY MEMBERS | June 2022 | October 2024 | Allow | 28 | 1 | 0 | No | No |
| 17846845 | APPARATUS AND METHOD FOR OOCYTE RESCUE IN VITRO POST STIMULATION | June 2022 | February 2024 | Abandon | 19 | 1 | 1 | No | No |
| 17808248 | ANTI-GITR ANTIBODIES AND METHODS OF USE THEREOF | June 2022 | November 2024 | Abandon | 28 | 0 | 1 | No | No |
| 17831254 | DIAGNOSTIC ASSAYS AND KITS FOR DETECTION OF FOLATE RECEPTOR 1 | June 2022 | March 2025 | Abandon | 33 | 1 | 1 | No | No |
| 17752074 | METHOD FOR THE PRODUCTION OF A GLYCOSYLATED IMMUNOGLOBULIN | May 2022 | March 2025 | Abandon | 34 | 0 | 1 | No | No |
| 17747764 | GPCR BINDING PROTEINS AND SYNTHESIS THEREOF | May 2022 | March 2025 | Abandon | 34 | 1 | 1 | No | No |
| 17733026 | FUSOKINES INVOLVING CYTOKINES WITH STRONGLY REDUCED RECEPTOR BINDING AFFINITIES | April 2022 | May 2025 | Allow | 36 | 2 | 1 | No | No |
| 17687934 | VARIANT ACTRIIB PROTEINS AND USES THEREOF | March 2022 | October 2024 | Allow | 31 | 1 | 1 | No | No |
| 17666705 | ALK4:ACTRIIB HETEROMULTIMERS AND USES THEREOF | February 2022 | November 2024 | Allow | 33 | 2 | 0 | No | No |
| 17632107 | RELAXIN ANALOGS AND METHODS OF USING THE SAME | February 2022 | January 2025 | Allow | 36 | 1 | 1 | No | No |
| 17579345 | ADAMTS Binding Immunoglobulins | January 2022 | September 2024 | Allow | 32 | 2 | 0 | No | No |
| 17561448 | AGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR 2 ANTIBODIES | December 2021 | December 2024 | Allow | 35 | 1 | 1 | No | No |
| 17561496 | COMPOSITIONS AND METHODS FOR TARGETING ACTIVIN SIGNALING TO TREAT CANCER | December 2021 | January 2025 | Allow | 37 | 1 | 1 | Yes | No |
| 17531365 | METHODS FOR THE TREATMENT OF THYROID EYE DISEASE | November 2021 | September 2024 | Allow | 34 | 2 | 0 | No | No |
| 17531368 | METHODS FOR THE TREATMENT OF THYROID EYE DISEASE | November 2021 | November 2024 | Allow | 36 | 1 | 1 | No | No |
| 17524883 | THERAPIES WITH LANTHIONINE C-LIKE PROTEIN 2 LIGANDS AND CELLS PREPARED THEREWITH | November 2021 | July 2024 | Allow | 32 | 1 | 0 | No | No |
| 17523226 | SINGLE-ARM TYPE I AND TYPE II RECEPTOR FUSION PROTEINS AND USES THEREOF | November 2021 | November 2024 | Allow | 36 | 2 | 1 | No | No |
| 17522600 | MONOCLONAL ANTI-IL-1RACP ANTIBODIES | November 2021 | October 2024 | Allow | 35 | 1 | 1 | No | No |
| 17517370 | Senescent Cell Biomarkers | November 2021 | January 2025 | Allow | 39 | 2 | 1 | Yes | No |
| 17474718 | IL1-R1 DERIVED INHIBITOR OF IL-1b AND USE THEREOF | September 2021 | January 2024 | Abandon | 28 | 0 | 1 | No | No |
| 17398294 | Bispecific EGFR/C-Met Antibodies | August 2021 | November 2023 | Abandon | 27 | 3 | 0 | No | No |
| 17358788 | METHODS AND COMPOSITIONS FOR INHIBITION OF EGF/EGFR PATHWAY IN COMBINATION WITH TYROSINE KINASE INHIBITORS | June 2021 | December 2024 | Allow | 41 | 3 | 1 | Yes | No |
| 17303970 | EXPRESSION OF NOVEL CELL TAGS | June 2021 | August 2024 | Allow | 38 | 3 | 1 | Yes | No |
| 17282249 | CHIMERIC ANTIGEN WITH ENHANCED MULTI-IMMUNE FUNCTION THROUGH SPECIFIC BINDING TO TARGET CELL, AND USE THEREOF | April 2021 | June 2025 | Abandon | 50 | 1 | 1 | No | No |
| 17198229 | ANTIBODIES TO GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR AND USES THEREOF | March 2021 | February 2025 | Allow | 47 | 2 | 1 | No | No |
| 17256547 | Vaccine Composition for Preventing or Treating Diseases Caused by Severe Fever with Thrombocytopenia Syndrome (SFTS) Viral Infection | December 2020 | May 2025 | Abandon | 53 | 1 | 1 | No | No |
| 17254762 | HEPATITIS B AND/OR HEPATITIS D-PERMISSIVE CELLS AND ANIMALS | December 2020 | March 2025 | Abandon | 51 | 1 | 1 | No | No |
| 17253811 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A TNF INHIBITOR | December 2020 | March 2025 | Abandon | 51 | 1 | 1 | No | No |
| 17059583 | NOVEL INTERLEUKIN-2 AND USE THEREOF | November 2020 | December 2024 | Allow | 48 | 1 | 1 | No | No |
| 17058130 | Endogenous Labelling of Extracellular Vesicles | November 2020 | January 2025 | Abandon | 50 | 0 | 1 | No | No |
| 17056632 | TREATMENT OF CIDP | November 2020 | February 2025 | Allow | 51 | 2 | 0 | No | No |
| 17053230 | EPITOPE RESTRICTION FOR ANTIBODY SELECTION | November 2020 | January 2025 | Allow | 50 | 2 | 1 | Yes | No |
| 17052783 | NOVEL BINDERS OF TGFBeta-SUPERFAMILY LIGANDS AND USES THEREOF | November 2020 | July 2024 | Allow | 44 | 2 | 1 | Yes | No |
| 16977265 | METHODS AND COMPOSITIONS FOR TREATING NATALIZUMAB-ASSOCIATED PROGRESSIVE MULTIFOCAL ENCEPHALOPATHY | September 2020 | November 2024 | Abandon | 50 | 1 | 1 | No | No |
| 16976983 | TECHNIQUES FOR GENERATING CELL-BASED THERAPEUTICS USING RECOMBINANT T CELL RECEPTOR GENES | August 2020 | August 2024 | Allow | 48 | 1 | 1 | No | No |
| 16855883 | COMPOSITIONS AND METHODS USEFUL IN PROMOTING MILK PRODUCTION | April 2020 | July 2024 | Allow | 51 | 2 | 1 | No | Yes |
| 16627266 | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY FOR CANCER | December 2019 | May 2024 | Allow | 53 | 4 | 1 | No | No |
| 16534230 | METHODS AND COMPOSITIONS FOR INHIBITION OF EGF/EGFR PATHWAY IN COMBINATION WITH ANAPLASTIC LYMPHOMA KINASE INHIBITORS | August 2019 | November 2024 | Allow | 60 | 7 | 1 | No | No |
| 16218287 | SOLUBLE MEDIATOR | December 2018 | May 2019 | Allow | 5 | 1 | 0 | No | No |
| 16015988 | COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF INFLAMMATORY BOWEL DISEASE | June 2018 | June 2019 | Allow | 12 | 1 | 1 | No | No |
| 15983688 | ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF | May 2018 | November 2018 | Allow | 6 | 0 | 0 | No | No |
| 15975591 | Soluble Mediator | May 2018 | February 2019 | Allow | 9 | 1 | 0 | No | No |
| 15958977 | NSP4 INHIBITORS AND METHODS OF USE | April 2018 | November 2018 | Allow | 7 | 0 | 0 | No | No |
| 15943137 | FGFR3 Binding Molecules | April 2018 | March 2020 | Allow | 24 | 1 | 1 | No | No |
| 15704917 | DIAGNOSTIC AND SCREENING METHODS FOR ATOPIC DERMATITIS | September 2017 | October 2018 | Allow | 14 | 1 | 1 | No | No |
| 15453451 | GITR Antibodies, Methods, and Uses | March 2017 | June 2019 | Allow | 27 | 1 | 1 | No | No |
| 15506266 | METHODS FOR IDENTIFYING A RECEPTOR FOR A LIGAND AND USES THEREOF | February 2017 | June 2019 | Allow | 28 | 2 | 1 | Yes | No |
| 15328997 | MEMORY INVARIANT NKT CELL MARKER | January 2017 | April 2019 | Allow | 27 | 1 | 1 | No | No |
| 15387095 | DOSAGE AND ADMINISTRATION OF ANTI-EGFR THERAPEUTICS | December 2016 | October 2017 | Allow | 10 | 1 | 0 | No | No |
| 15221832 | CANCER TARGETING BY ANTI-EGFR PEPTIDES AND APPLICATIONS THEREOF | July 2016 | May 2019 | Allow | 34 | 2 | 1 | No | No |
| 15094843 | NSP4 INHIBITORS AND METHODS OF USE | April 2016 | February 2018 | Allow | 23 | 1 | 1 | No | No |
| 14811967 | TFEB VARIANTS AND USES THEREOF | July 2015 | August 2015 | Allow | 1 | 0 | 0 | No | No |
| 14642776 | LRRC8 PROTEINS AND PROTEIN COMPLEXES AND METHODS FOR IDENTIFICATION OF CHANNEL MODULATORS | March 2015 | November 2017 | Allow | 32 | 1 | 1 | No | No |
| 14418684 | HISTOLOGICAL MARKERS FOR IDENTIFYING NON-SMALL CELL LUNG CARCINOMA PATIENTS FOR TREATMENT WITH AN ENTI-EGFR DRUG | January 2015 | November 2017 | Allow | 33 | 3 | 1 | Yes | No |
| 14535853 | GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS | November 2014 | May 2016 | Allow | 18 | 1 | 1 | No | No |
| 14375334 | CELL BASED SENSOR | October 2014 | March 2017 | Allow | 32 | 1 | 1 | No | No |
| 14513716 | COMBINATION THERAPY FOR BREAST CANCER | October 2014 | March 2015 | Allow | 5 | 0 | 1 | No | No |
| 14500000 | DIAGNOSTIC AND SCREENING METHODS FOR ATOPIC DERMATITIS | September 2014 | June 2017 | Allow | 33 | 2 | 1 | Yes | Yes |
| 14312191 | METHOD FOR ASSESSMENT OF POTENTIAL FOR DEVELOPMENT OF DRAVET SYNDROME AND USE THEREOF | June 2014 | October 2014 | Allow | 3 | 0 | 1 | No | No |
| 14305263 | RENAL CELL CARCINOMA BIOMARKERS | June 2014 | May 2015 | Allow | 11 | 2 | 1 | No | No |
| 14364888 | ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF | June 2014 | February 2018 | Allow | 44 | 3 | 1 | No | No |
| 14363346 | METHODS OF IDENTIFYING AND USING MDM2 INHIBITORS | June 2014 | November 2017 | Allow | 60 | 4 | 1 | Yes | No |
| 14178384 | USE OF LXR ANTAGONISTS FOR TREATMENT OF SIDE EFFECTS OF ELEVATED GLUCOCORTICOID LEVELS | February 2014 | May 2016 | Allow | 27 | 2 | 1 | Yes | No |
| 14235274 | NOVEL ANTI-CXCR4 ANTIBODY AND ITS USE FOR THE DETECTION AND DIAGNOSIS OF CANCER | January 2014 | August 2016 | Allow | 30 | 2 | 1 | No | No |
| 14163158 | Kv1.3 Antagonists and Methods of Use | January 2014 | January 2018 | Allow | 48 | 5 | 1 | No | Yes |
| 14007683 | Inhibitors of Metastasis, Methods of Generating Such Inhibitors and Their Therapeutic Applications | January 2014 | May 2017 | Allow | 44 | 4 | 1 | No | No |
| 14007932 | Compositions And Methods For Treating, Diagnosing And Monitoring Disease | January 2014 | June 2017 | Allow | 45 | 4 | 1 | Yes | No |
| 14116186 | ANTIBODIES AGAINST TROPOMYOSIN-RELATED KINASE B RECEPTORS | December 2013 | March 2015 | Allow | 16 | 2 | 0 | Yes | No |
| 14003505 | TFEB VARIANTS AND USES THEREOF | October 2013 | April 2015 | Allow | 20 | 1 | 1 | No | No |
| 13947603 | ONCOFETAL ANTIGEN/IMMATURE LAMININ RECEPTOR ANTIBODIES FOR DIAGNOSTIC AND CLINICAL APPLICATIONS | July 2013 | November 2014 | Allow | 16 | 2 | 1 | No | No |
| 13933789 | ANTI SYSTEM ASC AMINO ACID TRANSPORTER 2 (ASCT2) ANTIBODY | July 2013 | October 2013 | Allow | 4 | 0 | 0 | No | No |
| 13997489 | BIOASSAY METHOD FOR DETECTING PHYSIOLOGICALLY ACTIVE SUBSTANCE | June 2013 | December 2015 | Allow | 29 | 2 | 1 | Yes | No |
| 13888716 | ANTI-VEGFR-3 ANTIBODY COMPOSITIONS | May 2013 | April 2014 | Allow | 11 | 2 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner LI, RUIXIANG.
With a 66.7% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 47.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner LI, RUIXIANG works in Art Unit 1674 and has examined 253 patent applications in our dataset. With an allowance rate of 93.7%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 32 months.
Examiner LI, RUIXIANG's allowance rate of 93.7% places them in the 81% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by LI, RUIXIANG receive 1.96 office actions before reaching final disposition. This places the examiner in the 63% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by LI, RUIXIANG is 32 months. This places the examiner in the 30% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +8.4% benefit to allowance rate for applications examined by LI, RUIXIANG. This interview benefit is in the 41% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 31.8% of applications are subsequently allowed. This success rate is in the 58% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 59.3% of cases where such amendments are filed. This entry rate is in the 82% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 91.7% of appeals filed. This is in the 82% percentile among all examiners. Of these withdrawals, 63.6% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 62.3% are granted (fully or in part). This grant rate is in the 79% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 37.5% of allowed cases (in the 100% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.8% of allowed cases (in the 54% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.